Shigehiko Kato

Shigehiko Kato

Auto-generated profile, based on publicly available information

Shigehiko Kato

Yamagata University School of Medicine

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Atherosclerosis
Verified
Journal Article
Closed access
HHHiromasa Hasegawa
Hiromasa Hasegawa
TWTetsu Watanabe
Tetsu Watanabe
SKShigehiko Kato
Shigehiko Kato
TTTaku Toshima
Taku Toshima
MYMiyuki Yokoyama
Miyuki Yokoyama
IKIsao Kubota
Isao Kubota

1 April 2021 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
TKTasuku Kurokawa
Tasuku Kurokawa
TATakanori Arimoto
Takanori Arimoto
NHNaoaki Hashimoto
Naoaki Hashimoto
DKDaisuke Kutsuzawa
Daisuke Kutsuzawa
SKShigehiko Kato
Shigehiko Kato
MWMasafumi Watanabe
Masafumi Watanabe
(18) F-FDG-PET/CT is promising tool to visualize not only transvenous lead infection but also epicardial lead infection.

7 April 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
TSTaijyu Satoh
Taijyu Satoh
KSKoichiro Sugimura
Koichiro Sugimura
Yoshihiro FukumotoYoshihiro Fukumoto
Yoshihiro Fukumoto
KAKohtaro Abe
Kohtaro Abe
YDYoshihiro Dohi
Yoshihiro Dohi
SYSatoshi Yasuda
Satoshi Yasuda
Background: Group 2 pulmonary hypertension ( PH ), defined as PH caused due to left heart disease, remains a challenging condition. However, its prognostic impact and implications for emerging therapies are unclear. We aimed to evaluate the real‐world relationship between pulmonary vascular resistance ( PVR ) and prognosis in Group 2 PH and assess the efficacy of emerging therapies. Methods: Two prospective registries supported by Japanese PH societies were analyzed: a current (2018–2024; n=563) and a previous (2012–2016; n=425) registry. The composite end points were hospitalization for heart failure, all‐cause death, ventricular assist device implantation, or cardiac transplantation. Results: Stratified analyses using propensity score–matched data demonstrated a significant association between PVR >3 Wood units and prognosis in patients with Group 2 PH (6‐year event‐free rates, PVR > 3 Wood units versus PVR ≦ 3 Wood units, previous registry: 72.9% versus 61.4%; current registry: 75.2% versus 55.4%). Consistent patterns were observed in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction subgroups. The use of SGLT2 (sodium‐glucose cotransporter‐2) inhibitors in the current registry was associated with improved outcomes in patients with elevated PVR , showing event‐free rates of 73.8% versus 35.5% in those without treatment. Among multivariate analyses including major treatment options, SGLT2 inhibitor treatment exhibited significant associations with improvement of composite end points. Conclusions: Elevated PVR (>3 Wood units) identified a high‐risk subset of patients with Group 2 PH . The association between the use of SGLT2 inhibitors and better outcomes suggests a potential therapeutic role that warrants further investigation through controlled studies.